Tiziana Life Sciences (TLSA) announced that the U.S. Department of Defense, DoD, has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury, SCI. This funding builds on Tiziana’s strategy to expand the therapeutic potential of its intranasal anti-CD3 platform beyond autoimmune and neuroinflammatory diseases into large, underserved neurological indications. The DoD award will support a three-year study of intranasal anti-CD3 in the acute phase of SCI, aimed at patients who present to the hospital immediately following injury. Complementing this, a two-year Stepping Strong Breakthrough Award will expand research into the chronic phase, focusing on patients living with persistent neurological deficits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences CEO Increases Stake Amidst Ongoing Clinical Trials
- Tiziana Life Sciences reports CEO purchased 14,848 shares
- Tiziana Life Sciences CEO Buys Shares, Signaling Confidence in Innovative Therapies
- Tiziana Life Sciences announces purchase of shares by CEO
- Tiziana Life Sciences Chairman Increases Stake with Recent Share Purchase